Key Trends Shaping the Future Artificial Pancreas Device System Market From 2025-2034: Innovations in Automated Insulin Delivery Systems

Which drivers are expected to have the greatest impact on the over the artificial pancreas device system market's growth?
The escalating incidence of pancreatic cancer is anticipated to fuel the expansion of the artificial pancreas device system market in the future. Pancreatic cancer refers to a malignant tumor that emerges from the pancreas, a gland situated behind the stomach. This type of cancer results from a mix of lifestyle, medical, genetic, and environmental aspects, along with genetic alterations leading to inherited pancreatitis which can initiate chronic pancreas inflammation. The primary function of an artificial pancreas device system (APDS) is to assist diabetic individuals in controlling their blood sugar levels. It does so by independently monitoring glucose levels and administering the necessary insulin dosage. For example, Cancer Australia, a government body, reported in March 2024 that the number of new pancreatic cancer cases diagnosed in 2023 was 4,506, a surge from the 3,751 cases identified over the previous five years. Hence, the escalating incidence of pancreatic cancer is a significant factor propelling the expansion of the artificial pancreas device system market.

Get Your Artificial Pancreas Device System Market Report Here:
https://www.thebusinessresearchcompany.com/report/artificial-pancreas-device-system-global-market-report

What is the future CAGR of the artificial pancreas device system market, and how will it impact industry expansion?
In recent years, we have noticed significant growth in the artificial pancreas device system market. The market size is expected to expand from $1.81 billion in 2024 to $2.07 billion in 2025, with a compound annual growth rate (CAGR) of 14.1%. The surge during this historical period can be associated with a rising influx of investment, increased government involvement in clinical research, an increasing requirement for automated systems for glycemic control, intensive research and development activities from industry participants, and a growing elderly population.

The market for artificial pancreas device systems is anticipated to experience rapid expansion in the coming years, increasing to a valuation of $3.48 billion by 2029, with a compound annual growth rate (CAGR) of 13.9%. This projected growth during the forecasted period can be associated with the rising incidence of diabetes, an upsurge in pancreatic cancer cases, an increasing rate of diabetes and obesity, the heightened demand for minimally invasive (MI) drug delivery systems and innovative advancements in diabetes management technology. Key trends for the forecast period encompass technological breakthroughs, ramped-up research and development efforts, an increase in product approvals, strategic partnerships and collaborations, and expanded activities in tele consultancy for patient follow-up.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18229&type=smp

What are the most significant trends transforming the artificial pancreas device system market today?
Major firms involved in the artificial pancreas device system market are developing automated insulin delivery systems to improve diabetes management. These systems play a significant role by autonomously monitoring glucose levels in the blood and administering the correct insulin dosage. The goal is to mimic the role of a healthy pancreas, relieving the pressure of frequent blood sugar checks and manual insulin delivery for diabetic individuals. In May 2023, for instance, Beta Bionics, a medical equipment manufacturer based in the US, gained FDA 510(k) approval for its iLet Insulin-Only Bionic Pancreas System. This automated insulin delivery device was created to independently evaluate and deliver insulin doses to manage blood glucose levels. Operating as a closed-loop system, it adjusts insulin delivery automatically based on the glucose levels reported by a connected continuous glucose monitor (CGM). The system demands only the user's weight and an estimation of meal size to adjust insulin delivery autonomously.

Which key market segments comprise the artificial pancreas device system market and drive its revenue growth?
The artificial pancreas device system market covered in this report is segmented -

1) By Device Type: Threshold Suspend Device Systems, Control-To-Range Systems, Control-To-Target Systems
2) By Treatment Type: Bi-Hormonal, Insulin Only, Hybrid
3) By End-User: Hospitals, Medical Centers, Other End-Users

Subsegments:
1) By Threshold Suspend Device Systems: Insulin Pump with Threshold Suspend, Continuous Glucose Monitoring (CGM) Integrated Systems
2) By Control-To-Range Systems: Hybrid Closed-Loop Systems, Insulin Delivery Systems with Range Control, Real-Time Glucose Adjustment Systems
3) By Control-To-Target Systems: Fully Closed-Loop Artificial Pancreas Systems, Insulin Pumps with Targeted Glucose Control, Automated Glucose Regulation Systems

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18229

What regions are at the forefront of artificial pancreas device system market expansion?
North America was the largest region in the artificial pancreas device system market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial pancreas device system market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the leading players fueling growth in the artificial pancreas device system market?
Major companies operating in the artificial pancreas device system market are Johnson & Johnson, Abbott Laboratories, Medtronic plc, DexCom Inc., Insulet Corporation, Tandem Diabetes Care Inc., Juvenile Diabetes Research Foundation (JDRF), Beta Bionics Inc., Glooko Inc., Bigfoot Biomedical Inc., CeQur SA, Medtrum Technologies Inc., Diabeloop SA, Beta-O2 Technologies Ltd, Pancreum Inc., TypeZero Technologies LLC, Inreda Diabetic B.V., Defymed SAS, Admetsys Corporation, DreaMed Diabetes Ltd

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=18229&type=smp

What Is Covered In The Artificial Pancreas Device System Global Market Report?

•Market Size Forecast: Examine the artificial pancreas device system market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the artificial pancreas device system market for a structured understanding.
•Key Players Overview: Analyze major players in the artificial pancreas device system market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the artificial pancreas device system market.
•Segment Contributions: Evaluate how different segments drive overall growth in the artificial pancreas device system market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the artificial pancreas device system market.
•Industry Challenges: Identify potential risks and obstacles affecting the artificial pancreas device system market.
•Competitive Landscape: Review strategic developments in the artificial pancreas device system market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.